Xynomic Pharma, a Raleigh-Shanghai clinical stage oncology company, has dosed the first patient in a Phase I/II trial that combines its lead drug, abexinostat, with Imbruvica (ibrutinib), a Janssen BTK inhibitor. The combination will be tested in patients with relapsed/refractory mantle cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma at Memorial Sloan Kettering Cancer Center. Imbruvica is already approved for these indications. Abexinostat is a novel HDAC inhibitor in global pivotal trials against NHL and renal cell carcinoma. More details....
Stock Symbol: (NSDQ: XYN)
Share this with colleagues:
Original Article: Xynomic Starts US Trial of Abexinostat-Inbruvica Combo for Lymphoma